https://www.concept2clinic.com/wp-content/uploads/2016/05/NEUROQUEST-AND-CONCEPT-2-CLINIC-INC-ANNOUNCES-RESULTS-OF-EXTENSIVE-MARKET-RESEARCH.jpg533948Concept 2 Clinichttps://www.concept2clinic.com/wp-content/uploads/2019/07/C2C-Orange-Logo-1.pngConcept 2 Clinic2016-05-24 23:12:582019-11-25 16:39:52Neuroquest and Concept 2 Clinic Inc. Announces Results Of Extensive Market Research
https://www.concept2clinic.com/wp-content/uploads/2019/07/scientist-in-lab-with-pipette.jpg617925Concept 2 Clinichttps://www.concept2clinic.com/wp-content/uploads/2019/07/C2C-Orange-Logo-1.pngConcept 2 Clinic2019-06-11 12:15:022019-11-25 16:13:59Ironshore Pharmaceuticals Announces JORNAY PM™ (METHYLPHENIDATE HCL) CII, the first and only ADHD stimulant dosed in the evenings
https://www.concept2clinic.com/wp-content/uploads/2018/07/Concept-2-Clinic-Ironshore.jpg311707Concept 2 Clinichttps://www.concept2clinic.com/wp-content/uploads/2019/07/C2C-Orange-Logo-1.pngConcept 2 Clinic2019-05-15 08:30:482019-11-25 16:11:52Government of Canada approves new treatment options for opioid use disorder and supports research, treatment and harm reduction projects in Ontario
https://www.concept2clinic.com/wp-content/uploads/2019/07/science-microscope-slides.jpg617925Concept 2 Clinichttps://www.concept2clinic.com/wp-content/uploads/2019/07/C2C-Orange-Logo-1.pngConcept 2 Clinic2019-04-29 19:40:332019-11-25 16:14:59AVROBIO, Inc. Announces FDA Clearance of Investigational New Drug Application for AVR-RD-01 Gene Therapy for the Treatment of Fabry Disease
https://www.concept2clinic.com/wp-content/uploads/2019/02/Concept-2-Clinic-Avrobio.jpg311707Concept 2 Clinichttps://www.concept2clinic.com/wp-content/uploads/2019/07/C2C-Orange-Logo-1.pngConcept 2 Clinic2019-02-06 11:48:562019-11-25 16:31:34AVROBIO, Inc. Announces Updated Clinical Data from Ongoing Phase 1 and Phase 2 Studies for AVR-RD-01 Gene Therapy for Fabry Disease
https://www.concept2clinic.com/wp-content/uploads/2018/07/Concept-2-Clinic-Ironshore.jpg311707Concept 2 Clinichttps://www.concept2clinic.com/wp-content/uploads/2019/07/C2C-Orange-Logo-1.pngConcept 2 Clinic2018-07-12 11:51:382019-04-09 11:22:12Ironshore Pharmaceuticals Announces PDUFA Date of August 8, 2018 FOR HLD200
https://www.concept2clinic.com/wp-content/uploads/2018/05/Concept-2-Clinic-Sentient.jpg311707Concept 2 Clinichttps://www.concept2clinic.com/wp-content/uploads/2019/07/C2C-Orange-Logo-1.pngConcept 2 Clinic2018-05-16 11:52:242019-04-09 11:23:34Sentien Co-Founder Dr. Biju Parekkadan Gives a Live Interview at World Advanced Therapies & Regenerative Medicine Congress
https://www.concept2clinic.com/wp-content/uploads/2016/05/NEUROQUEST-AND-CONCEPT-2-CLINIC-INC-ANNOUNCES-RESULTS-OF-EXTENSIVE-MARKET-RESEARCH.jpg
533
948
Concept 2 Clinic
https://www.concept2clinic.com/wp-content/uploads/2019/07/C2C-Orange-Logo-1.png
Concept 2 Clinic2016-05-24 23:12:582019-11-25 16:39:52Neuroquest and Concept 2 Clinic Inc. Announces Results Of Extensive Market Research
https://www.concept2clinic.com/wp-content/uploads/2019/07/beard-grooming-oil.jpg
617
925
Concept 2 Clinic
https://www.concept2clinic.com/wp-content/uploads/2019/07/C2C-Orange-Logo-1.png
Concept 2 Clinic2019-07-22 12:20:572019-07-24 09:45:25Health Canada Fact Sheet: “All About Cannabidiol”
https://www.concept2clinic.com/wp-content/uploads/2019/07/scientist-in-lab-with-pipette.jpg
617
925
Concept 2 Clinic
https://www.concept2clinic.com/wp-content/uploads/2019/07/C2C-Orange-Logo-1.png
Concept 2 Clinic2019-06-11 12:15:022019-11-25 16:13:59Ironshore Pharmaceuticals Announces JORNAY PM™ (METHYLPHENIDATE HCL) CII, the first and only ADHD stimulant dosed in the evenings
https://www.concept2clinic.com/wp-content/uploads/2018/07/Concept-2-Clinic-Ironshore.jpg
311
707
Concept 2 Clinic
https://www.concept2clinic.com/wp-content/uploads/2019/07/C2C-Orange-Logo-1.png
Concept 2 Clinic2019-05-15 08:30:482019-11-25 16:11:52Government of Canada approves new treatment options for opioid use disorder and supports research, treatment and harm reduction projects in Ontario
https://www.concept2clinic.com/wp-content/uploads/2019/07/science-microscope-slides.jpg
617
925
Concept 2 Clinic
https://www.concept2clinic.com/wp-content/uploads/2019/07/C2C-Orange-Logo-1.png
Concept 2 Clinic2019-04-29 19:40:332019-11-25 16:14:59AVROBIO, Inc. Announces FDA Clearance of Investigational New Drug Application for AVR-RD-01 Gene Therapy for the Treatment of Fabry Disease
https://www.concept2clinic.com/wp-content/uploads/2019/02/Concept-2-Clinic-Avrobio.jpg
311
707
Concept 2 Clinic
https://www.concept2clinic.com/wp-content/uploads/2019/07/C2C-Orange-Logo-1.png
Concept 2 Clinic2019-02-06 11:48:562019-11-25 16:31:34AVROBIO, Inc. Announces Updated Clinical Data from Ongoing Phase 1 and Phase 2 Studies for AVR-RD-01 Gene Therapy for Fabry Disease
https://www.concept2clinic.com/wp-content/uploads/2018/08/Concept-2-Clinic-Milestone-Pharmaceuticals.jpg
311
707
Concept 2 Clinic
https://www.concept2clinic.com/wp-content/uploads/2019/07/C2C-Orange-Logo-1.png
Concept 2 Clinic2018-08-08 11:50:452019-04-09 11:22:49Milestone Pharmaceuticals Announces First Patient Randomized in the Phase 3 NODE-301 Clinical Trial Evaluating Etripamil for Termination of Paroxysmal Supraventricular Tachycardia (PSVT) Episodes
https://www.concept2clinic.com/wp-content/uploads/2018/05/Concept-2-Clinic-Sentient.jpg
311
707
Concept 2 Clinic
https://www.concept2clinic.com/wp-content/uploads/2019/07/C2C-Orange-Logo-1.png
Concept 2 Clinic2018-05-16 11:52:242019-04-09 11:23:34Sentien Co-Founder Dr. Biju Parekkadan Gives a Live Interview at World Advanced Therapies & Regenerative Medicine Congress